-
2008
28 August 2008: Announcement no. 2, 2008: Zealand Pharma today announced that Dr. David H...
-
Product Pipeline
Zealand's Pipeline comprises 1 compound in phase III, 2 compounds in phase II, 3 compounds ...
Wyeth Pharmaceuticals
Zealand Pharma entered into an agreement with Wyeth in April 2003. Under this agreement, Zealand Pharma granted Wyeth exclusive, worldwide rights to co-develop, manufacture and market ZP123 (Rotigaptide) for any indication, and in February 2004 extended this to new collaborative activities relating to gap-junction modulators.
In 2007 Wyeth has finalized a global multi-centre Phase IIa safety and tolerability trial with rotigaptide in patients with large myocardial infarcts.
In October 2007 Wyeth advanced the first orally available gap junction modifier ZP1609 (GAP-134) into phase I clinical trials in the US. GAP-134/ZP1609 has shown pharmacological effects in animal models of both ventricular and atrial arrhythmias, and with its oral formulation, the molecule represents a novel paradigm for the potential chronic prevention of cardiac arrhythmias.
Tip a friend
Fill in the form below to tip a friend about this page.
Subscribe
When this page is updated you will be updated by e-mail.